Trent Welsh
Contributor since: 2016
Latest Articles
Hi-Crush - Opportunity Might Be Knocking
Arrowhead Pharmaceuticals - Finally, Another Buying Opportunity
Hi-Crush Is Looking Like A Spring Loaded Trap Ready To Release
Why Dell Technologies Is A Safer Bet Than VMware At This Time
Disney: Playing The Game To Win
Are Future Pipeline Bottlenecks Enough To Be Bearish On Hi-Crush?
Arrowhead Pharmaceuticals - Pullbacks Are Becoming Rare, So Take Advantage If You Love The Potential
Dominion Energy - Time To Start Buying Into The Long-Term Story
Opportunity To Reload On Hi-Crush Partners Might Be Coming Soon
Hold On Tightly To Your Twenty-First Century Fox Shares
Sarepta Therapeutics - Enjoy Sub $100 A Share Valuation While It Lasts
Follow The M&A Yellow Brick Road From AT&T To Disney
MiMedx: Internal Investigation Nears Its End
What Are Some Of The Tradable Impacts Of Apple Moving To All OLED Screens This Fall?
Jacobs Engineering: CH2M Is Starting To Pay Margin Dividends
Bought AT&T After Selling Verizon
The Complex Dell Technologies And VMware Potential Deal Takes The Next Steps
Arrowhead Pharmaceuticals - Here Come The Institutions And What That Could Mean
Buy Fox Now, Not Disney
The Market Is Overreacting To MiMedx's Latest Bad News
Sarepta Therapeutics: The Art Of Rallying Off Of Bad News
Arrowhead Pharmaceuticals Ready To Break Out Of Its $7 Trading Range
5 Reasons To Buy Hi-Crush Now
MiMedx: More Explosive Price Action Might Soon Be Here
#DeleteFacebook And Other Fairy Tales
Hi-Crush: Keep Your Eyes On The Prize
Icahn Is A Win For Both VMware And Dell Shareholders
Why Is VMware Up Big Today?
Charter: Spec Play If T-Mobile/Sprint Merger Talks Fail
Arrowhead Pharmaceuticals: Sneaky Upside Present Over The Course Of 2018
Go For Goldman Among Banks
General Mills: Growth Acquisitions And Inverting Yield Curve Make This A Juicy Long-Term Possibility